NeuroTrials.ai The Neurology Trials Database
About Contact
Trials Latest Wiki Journal Evidence
AI-Powered Neurology Evidence Search

Headache Trials

July 2026 · 16 Trials · NeuroTrials.ai
FEATURED ARTICLE
Does early initiation of erenumab in patients with episodic migraine who failed 1 or 2 previous preventive treatments provide improved long-term efficacy, tolerability, adherence, and patient satisfaction compared with nonspecific oral migraine preventive medication?

APPRAISE

12-Month Prospective, Interventional, Global, Multicenter, Active-Controlled, Randomized Clinical Trial Comparing Sustained Benefit of 2 Treatment Paradigms (Erenumab qm vs Oral Prophylactics) in Adult Episodic Migraine Patients

JAMA Neurology · 2024

Bottom Line: Earlier use of erenumab in patients with episodic migraine who failed 1 or 2 previous preventive treatments provided significantly greater and sustained efficacy, safety, tolerability, and adherence compared with continuous oral preventive medications over 12 months

PATHOPHYSIOLOGY / BIOMARKERS 1

IIH Provoke

2026

In a small (n=16) double-blind, placebo-controlled, two-way crossover provocation study, IV CGRP triggered typical IIH headache in 44% of women and was accompanied by elevations in 8 pro-nociceptive a...

TRIGEMINAL NEURALGIA 1

Is IV fosphenytoin superior to placebo in reducing pain intensity at 120 minutes in patients with acute trigeminal neuralgia exacerbations?

IV Fosphenytoin for Trigeminal Neuralgia

2026

MIGRAINE 5

Is vaporized cannabis effective for the acute treatment of migraine attacks?

Cannabis for Acute Migraine

2026

Does a single intravenous infusion of Lu AG09222, an anti-PACAP monoclonal antibody, reduce migraine days in patients with prior preventive treatment failures?

HOPE

2024

Is vaporized cannabis (THC-dominant, CBD-dominant, or THC+CBD) superior to placebo for the acute treatment of migraine attacks?

CANNABIS MIGRAINE

2024

Is CGRP inhibitor use associated with an increased risk of cardiovascular events in patients with migraine?

CGRP-CV

2026

Can a CGRP antibody actually prevent migraines in children and teens?

SPACE - Fremanezumab Pediatric

2026

CHRONIC MIGRAINE 3

Which treatment strategyโ€”withdrawal, prevention (oral, anti-CGRP, botulinum toxin), education, neurostimulation, or combinationsโ€”is most effective at reducing monthly headache days in patients with medication-overuse headache?

MOH NMA Liu 2025

2025

Does adding a 28-day prednisone taper to galcanezumab improve outcomes in medication overuse headache compared with either treatment alone?

Steroids + Galcanezumab for MOH

2025

Is atogepant effective for preventive treatment of chronic migraine in patients with and without acute medication overuse?

PROGRESS

2024

CLUSTER HEADACHE 2

Do anti-CGRP monoclonal antibodies effectively prevent attacks in episodic and chronic cluster headache?

KOLAKOWSKI ET AL 2026 EFFICACY

2026

Can a CGRP antibody prevent episodic cluster headache attacks?

GALiC

2019

CLUSTER HEADACHE (CGRP) 1

Is eptinezumab 400 mg IV every 12 weeks safe, tolerable, and effective for long-term prevention of chronic cluster headache?

CHRONICLE

2025

MIGRAINE PROPHYLAXIS 2

Does fremanezumab reduce monthly migraine days and depressive symptoms in patients with migraine and comorbid DSM-5 major depressive disorder?

UNITE

2025

Is amitriptyline an effective migraine prophylactic, and is the benefit independent of its antidepressant action?

Amitriptyline Couch

1976

MIGRAINE 1

Does eptinezumab combined with brief patient education reduce migraine burden more than patient education alone in adults with chronic migraine and medication-overuse headache?

RESOLUTION

2026